Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Hepion Pharmaceuticals, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
0
0
0
Research and development
13.7
13.4
7.59
3.18
12
20.4
33.3
35.6
11.8
0.45
General and administrative
7.37
7.28
7
4.59
8.15
10
10.3
9.62
7.5
3.32
Operating expenses
21
14.6
7.77
20.1
30.4
45.5
48.4
19.3
4.16
Operating income
-21
-20.6
-14.6
-7.77
-20.1
-30.4
-45.5
-48.4
-19.3
-4.16
Interest expense
0.34
0.55
0.03
0.01
0.01
0.01
Other non-operating income
4.22
Pre-tax income
-16.8
-15
-9.99
-7.95
-20.3
-32.7
-45.1
-49.3
-16.2
-8.28
Income tax
-1.91
-1.95
-0.54
-0.91
0.03
0
-2.88
-0.41
-2.97
Net income
-14.9
-13.1
-9.45
-7.04
-20.4
-32.7
-42.2
-48.9
-13.2
-8.28
EBITDA
-21
-14.6
-7.74
-20.1
-30.3
-45.4
-48.4
-19.3
EPS, basic
-2,058.00
-98,186.00
-6,001.00
-2,118.00
-474.04
-595.07
-616.07
-107.35
-0.88
EPS, diluted
-2,431.00
-1,402.00
-6,162.00
-2,118.00
-474.04
-595.07
-616.07
-107.35
-0.88
Shares, basic (weighted)
0.01
9.68
0
0
0.01
0.07
0.08
0.08
0.12
9.41
Shares, diluted (weighted)
0.01
9.68
0.01
0
0.01
0.07
0.08
0.08
0.12
9.41
Balance sheet
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
13
5.95
2.83
13.9
40.7
91.3
51.2
14.8
0.41
1.83
Other current assets
0.21
0.11
0.14
0.47
1.91
6.1
5.31
2.7
1.21
1.24
Total current assets
13.2
6.06
2.97
14.4
42.6
97.5
56.5
17.5
1.61
3.07
Property, plant and equipment
0.07
0.06
0.03
0.06
0.11
0.15
0.08
0.03
Lease right-of-use assets
0.8
0.56
0.3
0.05
0.21
0
Goodwill
1.87
1.87
1.87
1.87
1.87
1.87
0
Other non-current assets
0.36
Total assets
18.4
11.3
8.19
20.6
48.6
104
60.2
18.1
1.61
3.07
Accounts payable
1.63
1.56
0.75
0.49
3.72
2.45
2.67
2.35
0.22
0.17
Accrued liabilities
1.32
1.05
0.66
0.85
0.66
2.51
4.8
2.44
0.02
0.08
Short-term debt
0
Total current liabilities
2.94
2.6
2.85
1.61
4.66
8.21
7.89
5.29
3.14
0.3
Lease liabilities
0.54
0.3
0.05
0
0.09
Total liabilities
9.33
7.55
6.21
4.99
8.12
10.6
10.4
10.8
3.48
0.4
Total debt
0
Paid-in capital
67.5
69.7
76.7
97.7
143
225
224
230
234
247
Retained earnings
-59.5
-67
-76.7
-83.8
-104
-134
-176
-225
-238
-246
Other comprehensive income
0
-0.09
-0.08
0.01
0.01
Shareholders' equity
9.06
3.7
1.72
15.6
40.5
93
49.9
7.28
-1.86
2.67
Total equity
9.06
3.7
1.72
15.6
40.5
93
49.9
7.28
-1.86
2.67
Total liabilities and equity
18.4
11.3
8.19
20.6
48.6
104
60.2
18.1
1.61
3.07
Shares outstanding
0.08
9.79
0
0
0.03
0.08
0.08
0.1
0.14
11.6
Cash flow statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-14.9
-13.1
-9.45
-7.04
-20.4
-32.7
-42.2
-48.9
-13.2
-8.28
Depreciation and amortization
0.03
0.02
0.03
0.03
0.09
0.08
0.07
0.03
Stock-based compensation
1.7
0.23
0.07
2.38
4.67
2.55
1.34
0.79
0.02
Change in payables
-2.13
-0.9
-0.32
3.04
-1.07
2.25
0.3
-4.55
0
Cash from operations
-19.2
-15.6
-7.57
-16.2
-31.2
-35
-40.9
-18.2
-3.27
Capital expenditures
-0.01
-0.05
-0.09
-0.13
-0.02
-0.01
Purchases of investments
-0.13
Cash from investing
-0.01
0
-0.05
-0.09
-0.13
-0.01
-0.01
-0.6
-0.13
Debt issued
2
1.25
0.18
0
Debt repaid
-0.67
-1.25
0
-0.18
0
Stock issued
24.7
1.64
7.68
42.9
82.2
0
4.49
1.85
9
Cash from financing
24.8
12.5
18.7
43.1
82
-5.14
4.49
4.35
4.83
Exchange rate effect
0
-0.05
0.01
0.09
Net change in cash
5.58
-3.12
11.1
26.8
50.6
-40.2
-36.4
-14.4
1.42
Free cash flow
-19.2
-7.62
-16.3
-31.4
-35
-40.9
Interest paid
0.13
0.03
0
0
0
0
0.02
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.06 on September 28, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-249.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-165.4%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value CAGR, 3y
-62.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-42.0%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
90.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-62.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-42.5%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
7,556.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
397.9%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
296.6%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.91x
Current assets / current liabilities.
Quick ratio
3.31x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.31x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.10
Cash from operations / diluted weighted shares.
Book value per share
$0.04
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
4.54x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
4.54x
Market cap / tangible book value, when positive.
Earnings yield
-55.0%
Net income / market cap (the inverse of P/E).
Was Hepion Pharmaceuticals, Inc. profitable in fiscal 2025?
No. It reported a net loss of $8.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.